Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry

Analytical and Bioanalytical Chemistry

Volumn 401, Issue 6, 2011, Pages 1923-1933

  Huang, Yong ^a   Yang, Qiyun ^a   Yoon, Kwangchae ^a   Lei, Yvonne ^a   Shi, Robert ^a   Gee, Winnie ^a   Lin, Emil T ^a   Greenblatt, Ruth M ^b,c   Gandhi, Monica ^b  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Antiretroviral drug; Hair; LC MS MS; Nevirapine; TDM

Indexed keywords

ADHERENCE; ANTIRETROVIRAL DRUGS; HAIR; LC-MS/MS; NEVIRAPINE;

ACETIC ACID; ACETONITRILE; AMMONIUM COMPOUNDS; DEUTERIUM; DISEASES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PATIENT MONITORING; SOLVENT EXTRACTION;

LIQUIDS;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE;

ARTICLE; CHEMISTRY; COHORT ANALYSIS; ECONOMICS; HAIR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANTI-HIV AGENTS; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; HAIR; HIV INFECTIONS; HUMANS; NEVIRAPINE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 80255126279     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-011-5278-7     Document Type: Article

References (37)

1. L Osterberg T Blaschke 2005 Adherence to medication New Engl J Med 353 487 497 10.1056/NEJMra050100 1:CAS:528:DC%2BD2MXntVCisL0%3D (Pubitemid 41127293)
2. J Cramer R Rosenheck G Kirk W Krol J Krystal 2003 Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes Value Health 6 566 573 10.1046/j.1524-4733.2003.65269.x (Pubitemid 37187719)
3. J Ickovics AW Meisler 1997 Adherence in AIDS clinical trials: a framework for clinical research and clinical care J Clin Epidemiology 50 385 391 10.1016/S0895-4356(97)00041-3 1:STN:280:DyaK2szit1KjtA%3D%3D (Pubitemid 27223267)
4. GF Vanhove JM Schapiro MA Winters TC Merigan TF Blaschke 1996 Patient compliance and drug failure in protease inhibitor monotherapy JAMA 276 1955 1956 10.1001/jama.276.24.1955 1:STN:280:DyaK2s7is1Wgug%3D%3D (Pubitemid 26427720)
5. DL Paterson S Swindells J Mohr M Brester EN Vergis C Squier MM Wagener N Singh 2000 Adherence to protease inhibitor therapy and outcomes in patients with HIV infection Ann Intern Med 133 21 30 1:STN:280:DC%2BD3czit1altA%3D%3D (Pubitemid 30432540)
6. JH Condra WA Schleif OM Blahy LJ Gabryelski DJ Graham RA QuinteroJC HL Robbins E Roth M Shivaprakash D Titus T Yang H Tepplert KE Squires PJ Deutsch EA Emini 1995 In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature 374 569 571 10.1038/374569a0 1:CAS:528:DyaK2MXkvVKqtrY%3D
7. JA Salomon DR Hogan J Stover KA Stanecki N Walker PD Ghys B Schwartländer 2005 Integrating HIV prevention and treatment: from slogans to impact PLoS Med. 2 e16 10.1371/journal.pmed.0020016 (Pubitemid 40412733)
8. J Castilla J Del Romero V Hernando B Marincovich S García C Rodríguez 2005 Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV J AIDS 40 96 101 (Pubitemid 41233212)
9. TJ Podsadecki BC Vrijens EP Tousset RA Rode GJ Hanna 2008 "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients HIV Clin Trials 9 238 246 10.1310/hct0904-238
10. SH Khoo J Lloyd M Dalton A Bonington E Hart S Gibbons P Flegg J Sweeney EG Wilkins DJ Back 2006 Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)-a randomized controlled trial of therapeutic drug monitoring and adherence support J AIDS 41 461 467 1:CAS:528:DC%2BD28XktVWhu74%3D
11. DM Burger PW Hugen RE Aarnoutse RM Hoetelmans NPT JambroesM G Schreij MM Schneider ME van der Ende JM Lange 2003 Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations Ther Drug Monit 25 73 80 10.1097/00007691-200302000-00011 1:CAS:528:DC%2BD3sXmtVWnsw%3D%3D (Pubitemid 36139829)
12. P Clevenbergh R Garraffo J Durant P Dellamonica 2002 PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results AIDS 16 2311 2315 10.1097/00002030- 200211220-00011 1:CAS:528:DC%2BD38XovVehs7Y%3D (Pubitemid 35449017)
13. D Back G Gatti C Fletcher R Garaffo R Haubrich R Hoetelmans M Kurowski A Luber C Merry CF Perno 2002 Therapeutic drug monitoring in HIV infection: current status and future directions AIDS 16 Suppl 1 S5 S37 10.1097/00002030- 200203001-00002 1:CAS:528:DC%2BD38XktVSls74%3D (Pubitemid 41202107)
14. D Back S Gibbons S Khoo 2006 An update on therapeutic drug monitoring for antiretroviral drugs Ther Drug Monit 28 468 473 10.1097/01.ftd.0000211825. 57984.41 (Pubitemid 44314939)
15. RE Nettles TL Kieffer T Parsons CJ JohnsonJ Jr JE Gallant KA Carson RF Siliciano C Flexner 2006 Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring Clin Infec Dis 42 1189 1196 10.1086/501458 1:CAS:528:DC%2BD28XktVKjsbY%3D
16. Y Nakahara 1999 Hair analysis for abused and therapeutic drugs J Chromatogr B Biomed Sci Appl 733 161 180 10.1016/S0378-4347(99)00059-6 1:CAS:528:DyaK1MXmvVKhtLc%3D (Pubitemid 29481772)
17. T Uematsu 1993 Therapeutic drug monitoring in hair samples. Principles and practice Clin Pharmacokin 25 83 87 10.2165/00003088-199325020-00001 1:STN:280:DyaK2c%2FgslGgsA%3D%3D (Pubitemid 23232388)
18. M Gandhi RM Greenblatt 2002 Hair it is: the long and short of monitoring antiretroviral treatment Ann Intern Med 137 696 697 (Pubitemid 35176105)
19. JH Beumer IJ Bosman RA Maes 2001 Hair as a biological specimen for therapeutic drug monitoring Int J Clin Pract 55 353 357 1:CAS:528: DC%2BD3MXmsVyht7c%3D (Pubitemid 32707640)
20. L Bernard A Vuagnat G Peytavin MC Hallouin D Bouhour TH Nguyen JL Vildé F Bricaire G Raguin P de Truchis D Ghez M Duong C Perronne 2002 Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy Ann Intern Med 137 656 659 1:CAS:528:DC%2BD38Xos1equ7w%3D (Pubitemid 35176098)
21. J Servais G Peytavin V Arendt T Staub F Schneider R Hemmer G Burtonboy JC Schmit 2001 Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance AIDS 15 941 943 10.1097/00002030-200105040-00019 1:STN:280:DC%2BD3MzjtVCksQ%3D%3D (Pubitemid 32424402)
22. X Duval G Peytavin G Breton JL Ecobichon D Descamps G Thabut C Leport 2007 Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination AIDS 21 106 108 10.1097/QAD.0b013e3280118486 1:CAS:528:DC%2BD28Xht1Ogs7%2FP (Pubitemid 44912545)
23. Y Huang M Gandhi RM Greenblatt W Gee ET Lin N Messenkoff 2008 Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry Rapid Commun Mass Spectrom 22 3401 3409 10.1002/rcm.3750 1:CAS:528:DC%2BD1cXhtlOqtb3E
24. M Gandhi N Ameli P Bacchetti SJ Gange K Anastos A Levine CL Hyman M Cohen M Young Y Huang RM Greenblatt 2009 Protease inhibitor levels in hair strongly predict virologic response to treatment AIDS 23 471 478 10.1097/QAD. 0b013e328325a4a9 1:CAS:528:DC%2BD1MXit1Cnsro%3D
25. Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, Young M, Milam J, Cohen MH, Sharp GB, Huang Y, Greenblatt RM (2011) Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis 52:1267-1275
26. Gandhi M, Ameli N, Bacchetti P, Huang Y, Gange SJ, Anastos K, Levine A, Cohen M, Young M, Greenblatt RM (2009) Concentrations of Efavirenz in Hair Are Strongly Correlated with Virologic Response. 16th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, Canada, February 8-11
27. GU van Zyl TE van Mens H Mcilleron M Zeier JB Nachega E Decloedt C Malavazzi P Smith Y Huang L van der Merwe M Gandhi G Maartens 2011 Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting J AIDS 56 333 339
28. R Murphy J Montaner 1996 Nevirapine: a review of its development, pharmacological profile and potential for clinical use J Expert Opinion on Investigational Drugs 5 1183 1199 10.1517/13543784.5.9.1183 1:CAS:528: DyaK28Xls1ymsLg%3D (Pubitemid 26302639)
29. JL Sullivan 2003 Prevention of mother-to-child transmission of HIV-what next? J AIDS 34 Suppl 1 S67 S72
30. M Duong M Buisson G Peytavin E Kohli L Piroth B Martha M Grappin P Chavanet H Portier 2005 Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors Ann Pharmacother 39 603 609 10.1345/aph.1E563 1:CAS:528:DC%2BD2MXjt1Wls7c%3D (Pubitemid 40396611)
31. D Gonzalez de Requena M Nunez I Jimenez-Nacher V Soriano 2002 Liver toxicity caused by nevirapine AIDS 16 290 291 10.1097/00002030-200201250-00020 (Pubitemid 34118577)
32. JM McKoy CL Bennett MH Scheetz V Differding KL Chandler KK Scarsi PR Yarnold S Sutton F Palella S Johnson E Obadina DW Raisch JP Parada 2009 Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project Drug Saf 32 147 158 10.2165/00002018-200932020-00007 1:CAS:528:DC%2BD1MXkvVKjsLw%3D
33. E Martínez JL Blanco JA Arnaiz JB Pérez-Cuevas A Mocroft A Cruceta MA Marcos A Milinkovic MA García-Viejo J Mallolas X Carné A Phillips JM Gatell 2001 Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy AIDS 15 1261 1268 10.1097/00002030-200107060-00007 (Pubitemid 32592358)
34. SE Barkan Preston-Martin S MelnickSL K Weber LA Kalish P Miotti M Young R Greenblatt H Sacks J Feldman 1998 The Women's Interagency HIV Study. WIHS Collaborative Study Group Epidemiology 9 117 125 10.1097/00001648-199803000- 00004 1:STN:280:DyaK1c7msFSgug%3D%3D (Pubitemid 28157608)
35. CT Viswanathan S Bansal B Booth AJ DeStefano MJ Rose J Sailstad VP Shah JP Skelly PG Swann R Weiner 2007 Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays AAPS J9 E30 E42 10.1208/aapsj0901004 (Pubitemid 46296546)
36. N Spooner 2010 A glowing future for dried blood spot sampling Bioanalysis 2 1343 1344 10.4155/bio.10.111 1:CAS:528:DC%2BC3cXhtVCnt73E
37. P Amsterdam C Waldrop 2010 The application of dried blood spot sampling in global clinical trials Bioanalysis 2 1783 1786 10.4155/bio.10.158